188 related articles for article (PubMed ID: 37815829)
1. Differential Use of Radiotherapy Fractionation Regimens in Prostate Cancer.
Qureshy SA; Diven MA; Ma X; Marciscano AE; Hu JC; McClure TD; Barbieri C; Nagar H
JAMA Netw Open; 2023 Oct; 6(10):e2337165. PubMed ID: 37815829
[TBL] [Abstract][Full Text] [Related]
2. Increasing Use of Shorter-Course Radiotherapy for Prostate Cancer.
Yu JB; Sun Y; Jia AY; Vince RA; Shoag JE; Zaorsky NG; Spratt DE
JAMA Oncol; 2023 Dec; 9(12):1696-1701. PubMed ID: 37796479
[TBL] [Abstract][Full Text] [Related]
3. Current use of stereotactic body radiation therapy for low and intermediate risk prostate cancer: A National Cancer Database Analysis.
Malouff TD; Stross WC; Seneviratne DS; Waddle MR; May BC; Buskirk SJ; Tzou KS
Prostate Cancer Prostatic Dis; 2020 Jun; 23(2):349-355. PubMed ID: 31780782
[TBL] [Abstract][Full Text] [Related]
4. Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5-year outcomes of the HYPO-RT-PC randomised, non-inferiority, phase 3 trial.
Widmark A; Gunnlaugsson A; Beckman L; Thellenberg-Karlsson C; Hoyer M; Lagerlund M; Kindblom J; Ginman C; Johansson B; Björnlinger K; Seke M; Agrup M; Fransson P; Tavelin B; Norman D; Zackrisson B; Anderson H; Kjellén E; Franzén L; Nilsson P
Lancet; 2019 Aug; 394(10196):385-395. PubMed ID: 31227373
[TBL] [Abstract][Full Text] [Related]
5. Hypofractionation for clinically localized prostate cancer.
Hickey BE; James ML; Daly T; Soh FY; Jeffery M
Cochrane Database Syst Rev; 2019 Sep; 9(9):CD011462. PubMed ID: 31476800
[TBL] [Abstract][Full Text] [Related]
6. Hypofractionated SBRT versus conventionally fractionated EBRT for prostate cancer: comparison of PSA slope and nadir.
Anwar M; Weinberg V; Chang AJ; Hsu IC; Roach M; Gottschalk A
Radiat Oncol; 2014 Feb; 9():42. PubMed ID: 24484652
[TBL] [Abstract][Full Text] [Related]
7. Stereotactic body radiotherapy versus conventional/moderate fractionated radiation therapy with androgen deprivation therapy for unfavorable risk prostate cancer.
Patel SA; Switchenko JM; Fischer-Valuck B; Zhang C; Rose BS; Chen RC; Jani AB; Royce TJ
Radiat Oncol; 2020 Sep; 15(1):217. PubMed ID: 32933541
[TBL] [Abstract][Full Text] [Related]
8. Trends in the Use of Stereotactic Body Radiotherapy for Treatment of Prostate Cancer in the United States.
Mahase SS; D'Angelo D; Kang J; Hu JC; Barbieri CE; Nagar H
JAMA Netw Open; 2020 Feb; 3(2):e1920471. PubMed ID: 32022878
[TBL] [Abstract][Full Text] [Related]
9. Is moderate hypofractionation accepted as a new standard of care in north america for prostate cancer patients treated with external beam radiotherapy? Survey of genitourinary expert radiation oncologists.
McClelland S; Sandler KA; Degnin C; Chen Y; Hung AY; Mitin TE
Int Braz J Urol; 2019; 45(2):273-287. PubMed ID: 30676300
[TBL] [Abstract][Full Text] [Related]
10. Acute genitourinary toxicity after high-dose-rate (HDR) brachytherapy combined with hypofractionated external-beam radiation therapy for localized prostate cancer: correlation between the urethral dose in HDR brachytherapy and the severity of acute genitourinary toxicity.
Akimoto T; Ito K; Saitoh J; Noda SE; Harashima K; Sakurai H; Nakayama Y; Yamamoto T; Suzuki K; Nakano T; Niibe H
Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):463-71. PubMed ID: 16168838
[TBL] [Abstract][Full Text] [Related]
11. Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer (HYPO-RT-PC): patient-reported quality-of-life outcomes of a randomised, controlled, non-inferiority, phase 3 trial.
Fransson P; Nilsson P; Gunnlaugsson A; Beckman L; Tavelin B; Norman D; Thellenberg-Karlsson C; Hoyer M; Lagerlund M; Kindblom J; Ginman C; Johansson B; Björnlinger K; Seke M; Agrup M; Zackrisson B; Kjellén E; Franzén L; Widmark A
Lancet Oncol; 2021 Feb; 22(2):235-245. PubMed ID: 33444529
[TBL] [Abstract][Full Text] [Related]
12. A Randomized Phase II Trial of Prostate Boost Irradiation With Stereotactic Body Radiotherapy (SBRT) or Conventional Fractionation (CF) External Beam Radiotherapy (EBRT) in Locally Advanced Prostate Cancer: The PBS Trial (NCT03380806).
Isfahanian N; Lukka H; Dayes I; Quan K; Schnarr KL; Douvi G; Goldberg M; Wright J; Swaminath A; Chow T; Diamond K; Cutz JC; Kavsak P; Thabane L; Tsakiridis T
Clin Genitourin Cancer; 2020 Aug; 18(4):e410-e415. PubMed ID: 32265129
[TBL] [Abstract][Full Text] [Related]
13. Moderate versus extreme hypofractionated radiotherapy: a toxicity comparative analysis in low- and favorable intermediate-risk prostate cancer patients.
Nicosia L; Mazzola R; Rigo M; Figlia V; Giaj-Levra N; Napoli G; Ricchetti F; Corradini S; Ruggieri R; Alongi F
J Cancer Res Clin Oncol; 2019 Oct; 145(10):2547-2554. PubMed ID: 31324979
[TBL] [Abstract][Full Text] [Related]
14. Factors Influencing Noncompletion of Radiation Therapy Among Men With Localized Prostate Cancer.
Dee EC; Muralidhar V; Arega MA; Kishan AU; Spratt DE; Dess RT; King MT; Sha ST; Santos PMG; Butler SS; Sanford NN; Nguyen PL; Mahal BA
Int J Radiat Oncol Biol Phys; 2021 Apr; 109(5):1279-1285. PubMed ID: 33276019
[TBL] [Abstract][Full Text] [Related]
15. Hypofractionated Radiotherapy for Localized Prostate Cancer: When and for Whom?
Roy S; Morgan SC
Curr Urol Rep; 2019 Jul; 20(9):53. PubMed ID: 31359187
[TBL] [Abstract][Full Text] [Related]
16. Patient-reported quality of life after stereotactic body radiation therapy versus moderate hypofractionation for clinically localized prostate cancer.
Johnson SB; Soulos PR; Shafman TD; Mantz CA; Dosoretz AP; Ross R; Finkelstein SE; Collins SP; Suy S; Brower JV; Ritter MA; King CR; Kupelian PA; Horwitz EM; Pollack A; Abramowitz MC; Hallman MA; Faria S; Gross CP; Yu JB
Radiother Oncol; 2016 Nov; 121(2):294-298. PubMed ID: 27890426
[TBL] [Abstract][Full Text] [Related]
17. Shorter Radiation Regimens and Treatment Noncompletion Among Patients With Breast and Prostate Cancer in the United States: An Analysis of Racial Disparities in Access and Quality.
Dee EC; Taunk NK; Chino FL; Deville C; McClelland S; Muralidhar V; McBride SN; Gillespie EF; Yamoah K; Nguyen PL; Mahal BA; Winkfield KM; Vapiwala N; Santos PMG
JCO Oncol Pract; 2023 Feb; 19(2):e197-e212. PubMed ID: 36399692
[TBL] [Abstract][Full Text] [Related]
18. The march toward single-fraction stereotactic body radiotherapy for localized prostate cancer-Quo Vadimus?
Ong WL; Loblaw A
World J Urol; 2023 Dec; 41(12):3485-3491. PubMed ID: 37921936
[TBL] [Abstract][Full Text] [Related]
19. Intensity-modulated fractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): acute toxicity findings from an international, randomised, open-label, phase 3, non-inferiority trial.
Brand DH; Tree AC; Ostler P; van der Voet H; Loblaw A; Chu W; Ford D; Tolan S; Jain S; Martin A; Staffurth J; Camilleri P; Kancherla K; Frew J; Chan A; Dayes IS; Henderson D; Brown S; Cruickshank C; Burnett S; Duffton A; Griffin C; Hinder V; Morrison K; Naismith O; Hall E; van As N;
Lancet Oncol; 2019 Nov; 20(11):1531-1543. PubMed ID: 31540791
[TBL] [Abstract][Full Text] [Related]
20. Brachytherapy boost (BT-boost) or stereotactic body radiation therapy boost (SBRT-boost) for high-risk prostate cancer (HR-PCa).
Peyraga G; Lizee T; Khalifa J; Blais E; Mauriange-Turpin G; Supiot S; Krhili S; Tremolieres P; Graff-Cailleaud P
Cancer Radiother; 2021 Jun; 25(4):400-409. PubMed ID: 33478838
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
